---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-003515"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:46:28.285675+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Actuate Therapeutics appoints former Mersana CEO Martin Huber to board

## Summary
- Board expanded from 7 to 8; Huber appointed as Class III director effective May 1, 2026.
- Huber previously President/CEO of Mersana until Jan 2026 acquisition by Day One Biopharmaceuticals.
- Receives initial option grant of 30,000 shares (3-year vest), annual retainer $44,000, plus $3,000/quarter consulting fee.
- He will serve on Nominating and Corporate Governance Committee; expertise includes approvals of pembrolizumab, niraparib, others.
- Company highlights his role in advancing elraglusib for difficult-to-treat cancers including metastatic pancreatic cancer.

## SEC filing metadata
- accession: 0001683168-26-003515
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/0001683168-26-003515-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/actuate_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-003515
- JSON: https://secwatch.observer/filing/0001683168-26-003515.json
- Plain text: https://secwatch.observer/filing/0001683168-26-003515.txt

## Key facts
- Executive change
  Martin H. Huber was appointed as Class III Director at ACTUATE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Class III Director
  source text: On May 1, 2026, the Board of Directors ("Board") of Actuate Therapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/0001683168-26-003515-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.